Jacqueline Claudia Barrientos

Professor

Northwell Health

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Jacqueline Claudia Barrientos is a faculty member at Northwell Health in the United States. Her research focuses on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as evidenced by her recent publications on treatment selection, disease control, and real-world treatment patterns. She is also involved in investigating the effects of COVID-19 on hematologic conditions, highlighting important findings related to vaccination and complications.

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Esteban Braggio

Assistant Professor

Mayo Clinic

UNITED STATES

View details

Richard Burack

Professor

University of Rochester Medical Center

UNITED STATES

View details

schuh Anna

University of Oxford

UNITED KINGDOM

View details

Deborah Stephens

Assistant Professor

Huntsman Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jacqueline Claudia Barrientos

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry

Refractory immune thrombocytopenic purpura (ITP) secondary to prior COVID-19 infection requiring a splenectomy

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

Haemophagocytic lymphohistiocytosis following COVID-19 mRNA vaccination

Henoch-Schönlein purpura presenting post COVID-19 vaccination

Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target.

No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.

Chemotherapy-free frontline therapy for CLL: is it worth it?

Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy.

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.

Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.

Collaborators (4)

Esteban Braggio

Richard Burack

schuh Anna

Deborah Stephens

Make your next move.